ATXS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.482

+9.66%

-0.573

-1.29%

-0.585

+2.63%

Estimates Revision

The market is revising Downward the revenue expectations for Astria Therapeutics, Inc. (ATXS) for FY2025, with the revenue forecasts being adjusted by -24.76% over the past three months. During the same period, the stock price has changed by 55.98%.

Revenue Estimates for FY2025

Revise Downward

-24.76%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.24%

In Past 3 Month

Stock Price

Go Up

+55.98%

In Past 3 Month

9 Analyst Rating

Wall Street analysts forecast ATXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATXS is 20.00 USD with a low forecast of 13.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

7 Hold

0 Sell

Hold

Current: 0.000

Low

13.00

Averages

20.00

High

35.00

Current: 0.000

Low

13.00

Averages

20.00

High

35.00

Cantor Fitzgerald

Overweight

Neutral

downgrade

2025-11-12

Reason

Cantor Fitzgerald

Price Target

2025-11-12

downgrade

Overweight

Neutral

Reason

Cantor Fitzgerald downgraded Astria Therapeutics to Neutral from Overweight.

H.C. Wainwright

Buy -> Neutral

downgrade

2025-10-16

Reason

H.C. Wainwright

Price Target

2025-10-16

downgrade

Buy -> Neutral

Reason

H.C. Wainwright downgraded Astria Therapeutics to Neutral from Buy without a price target after the company agreed to be acquired by BioCryst (BCRX) for a mix of cash and stock representing an implied value of $13 per share.

Citizens JMP

Outperform -> Market Perform

downgrade

2025-10-15

Reason

Citizens JMP

Price Target

2025-10-15

downgrade

Outperform -> Market Perform

Reason

Citizens JMP downgraded Astria Therapeutics (ATXS) to Market Perform from Outperform without a price target afire after the company reached an agreement to be acquired by BioCryst (BCRX) for cash and stock at an implied value of $13 per share, or $700M. The firm views it as highly likely that the transaction will close as announced.

Citizens JMP

Jonathan Wolleben

Outperform

upgrade

$17 -> $27

2025-10-15

Reason

Citizens JMP

Jonathan Wolleben

Price Target

$17 -> $27

2025-10-15

upgrade

Outperform

Reason

Citizens JMP analyst Jonathan Wolleben raised the firm's price target on BioCryst (BCRX) to $27 from $17 and keeps an Outperform rating on the shares. BioCryst is buying Astria Therapeutics (ATXS) to "supercharge" its earnings growth with long- acting HAE candidate navenibart, the analyst tells investors in a research note. The firm expects 3 month and 6 month navenibart doses to hit in Astria's ongoing Phase 3 trial in early 2027 and believe its differentiated, long-acting convenience, coupled with impressive efficacy, will drive broad adoption right as BioCryst's Orladeyo hits its peak penetration.

Wedbush

Outperform -> Neutral

downgrade

$28 -> $13

2025-10-15

Reason

Wedbush

Price Target

$28 -> $13

2025-10-15

downgrade

Outperform -> Neutral

Reason

Wedbush downgraded Astria Therapeutics (ATXS) to Neutral from Outperform with a price target of $13, down from $28, after the company reached an agreement to be acquired by BioCryst (BCRX) for cash and stock at an implied value of $13 per share, or $700M.

RBC Capital

Outperform

maintain

$14 -> $15

2025-10-14

Reason

RBC Capital

Price Target

$14 -> $15

2025-10-14

maintain

Outperform

Reason

RBC Capital raised the firm's price target on BioCryst (BCRX) to $15 from $14 and keeps an Outperform rating on the shares. Following the announced transaction to acquire Astria Therapeutics (ATXS), their conference call discussing terms, and the firm's discussion with BioCryst's management team, RBC has further conviction that despite the near-term dilution tradeoff, this is a very sound deal that should leverage BioCryst's core competencies well, and set up their franchise even better. The firm added that Tuesday's weakness in BioCryst shares presents a compelling buying opportunity.

Valuation Metrics

The current forward P/E ratio for Astria Therapeutics Inc (ATXS.O) is -5.76, compared to its 5-year average forward P/E of -3.85. For a more detailed relative valuation and DCF analysis to assess Astria Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.85

Current PE

-5.76

Overvalued PE

-1.90

Undervalued PE

-5.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.87

Current EV/EBITDA

-3.49

Overvalued EV/EBITDA

-0.30

Undervalued EV/EBITDA

-3.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

11.66

Current PS

216.42

Overvalued PS

56.73

Undervalued PS

-33.42

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ATXS News & Events

Events Timeline

No data

News

7.0

01-08PRnewswire

Halper Sadeh Investigates CSG and Others for Shareholder Rights Violations

8.5

01-07PRnewswire

Astria Therapeutics to be Sold to BioCryst for $8.55 per Share

8.5

2025-12-20Globenewswire

Astria Therapeutics to be Acquired by BioCryst for $8.55 Cash per Share

People Also Watch

Frequently Asked Questions

What is Astria Therapeutics Inc (ATXS) stock price today?

The current price of ATXS is 13.18 USD — it has increased 1.54 % in the last trading day.

What is Astria Therapeutics Inc (ATXS)'s business?

Astria Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. It owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.

What is the price predicton of ATXS Stock?

What is Astria Therapeutics Inc (ATXS)'s revenue for the last quarter?

Astria Therapeutics Inc revenue for the last quarter amounts to 706.00K USD, decreased % YoY.

What is Astria Therapeutics Inc (ATXS)'s earnings per share (EPS) for the last quarter?

Astria Therapeutics Inc. EPS for the last quarter amounts to -0.55 USD, increased 30.95 % YoY.

What changes have occurred in the market's expectations for Astria Therapeutics Inc (ATXS)'s fundamentals?

How many employees does Astria Therapeutics Inc (ATXS). have?

Astria Therapeutics Inc (ATXS) has 78 emplpoyees as of January 09 2026.

What is Astria Therapeutics Inc (ATXS) market cap?

Today ATXS has the market capitalization of 740.96M USD.